Skip to content

News

OCRF Researchers Review Preclinical Models Used in Ovarian ...

OCRF Researchers Review Preclinical Models Used in Ovarian Cancer Research

In a review article published online in Oncogene on August 12, OCRF-funded researchers provide a comprehensive review of pre-clinical models used in ovarian cancer research.  The authors, including OCRF grantees Ernst Lengyel, Daniela Matei, Ken Nephew, and Joanna Burdette, explore current experimental models and reflect on the strengths and weaknesses for each method.  In addition, … Continued

OCRA News

Dogs Smell Ovarian Cancer Tissue

Dogs Smell Ovarian Cancer Tissue

Two dogs at the University of Pennsylvania’s Penn Vet Working Dog Center are learning how to smell tissue that is in early stages of ovarian cancer.  The dogs have been able to smell the cancerous tissue 100% of the time.  The dogs are part of an interdisciplinary research project to help scientists discover a chemical … Continued

Research

Time Interval from Surgery to Chemo Impacts Prognosis in Ov...

Time Interval from Surgery to Chemo Impacts Prognosis in Ovarian Cancer

Researchers in Austria investigated whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome in patients with advanced serous ovarian cancer. Data from 191 patients with stage III or IV ovarian cancer who underwent surgery followed by platinum-based chemotherapy were analysed.  The results, which were published in Gynecologic Oncology on … Continued

Research

Partner Member Profile: Promises of Hope

Partner Member Profile: Promises of Hope

Alicia Baines was inspired to start Promises of Hope by the people in her community: “I recognized that my community is in need,” she recalls. “People are afraid to talk about cancer. It’s not until someone passes away that they realize they probably should have done more.” Promises of Hope is dedicated to serving Prince … Continued

Community

Ovarian Cancer Therapies in Development

Ovarian Cancer Therapies in Development

Dr. Coleman, a member of the Alliance’s Scientific and Medical Advisory Board, conducted an interview on ovarian cancer therapies for the Cancer Network. He discussed the heterogeneity of ovarian cancer, angiogenesis inhibitors and new drugs in the pipeline. The full interview can be found here

Research

Analysis Points to New Cell Lines as Tumor Models for Ovari...

Analysis Points to New Cell Lines as Tumor Models for Ovarian Cancer Research

Research published online last week in Nature Communications suggests that some of the cell lines most frequently used to study high-grade serous ovarian cancer (HGSOC) may not be the best.  OCRF grantee and SAC member Douglas Levine, MD was one of the authors of the paper. Cell lines derived from tumor tissue are the most … Continued

Research

Progesterone and Estrogen Receptors are Prognostic Biomarke...

Progesterone and Estrogen Receptors are Prognostic Biomarkers for Some Ovarian Cancers

In an article published last week in The Lancet, an international group of investigators examined whether ovarian cancer tumors’ expression of the progesterone receptor (PR) and estrogen receptor (ER) was associated with survival in various subtypes of ovarian cancer.  To date, few biomarkers of ovarian cancer prognosis have been established. The study, which included 2,933 women, … Continued

Research

The Valerie Goldfein Story: Founder of the Woman to Woman P...

The Valerie Goldfein Story: Founder of the Woman to Woman Program

“November 4, 1999 was one of those perfect autumn days in New York when it seems as though nothing could go wrong. But it did for me. That was the day I was diagnosed with ovarian cancer and the world as I knew it would never be the same,” says Valerie. “No one could have … Continued

Community

Ovarian Cancer Research Fund and National Sponsor QVC Expan...

Ovarian Cancer Research Fund and National Sponsor QVC Expand Woman to Woman Program

Gynecologic Cancer Patients to Receive New Support in Tampa, Fla. and in Stanford, Calif. WEST CHESTER, Pa (Thursday, July 11, 2013) —Ovarian Cancer Research Fund (OCRF) and QVC today announced two new Woman to Woman grant recipients, Moffitt Cancer Center in Tampa, Fla. and Stanford Women’s Cancer Center in Stanford, Calif. QVC united with OCRF … Continued

OCRA News

After Angelina: What Do You Need to Know About Ovarian and ...

After Angelina: What Do You Need to Know About Ovarian and Breast Cancer Risk?

Experts agree: “If you or a close relative has been diagnosed with ovarian cancer, speak to your doctor about getting genetic counseling.” In the wake of Angelina Jolie’s announcement that she carries a genetic mutation linked to breast and ovarian cancers, thousands of women are wondering whether they are at risk. To address their concerns, … Continued

Community

Family History of Breast Cancer but no Genetic Mutation Doe...

Family History of Breast Cancer but no Genetic Mutation Does Not Raise Risk of Ovarian Cancer

Women with a family history of breast cancer but no BRCA1/2 mutation were found to be at average risk for developing ovarian cancer. The prospective study of 8005 women from a breast cancer family history clinic found that women with a BRCA2 mutation had a 17-times higher risk of developing ovarian cancer than average, and … Continued

Research

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.